focus -WSS

focus

author：focus 2025-10-01 10:36:26 - browse：7452

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Fauci's latest grilling in Congress: 9 hours, behind closed doors

focus

WSS

Long Covid research funding gets a major boost from NIH

Stories you might have missed in 2023: health, science, medicine

Latigo launches with $135 million for Vertex

At JPM 2024, hospital systems pitch financial strength to investors

Congress considering partial increase for doctor pay in Medicare

Life science postdocs should get big pay hike, NIH panel says

Wikipedia

focus

hotspot

In Memoriam: Notable people who died in 2023

Long Covid research funding gets a major boost from NIH

Anesthesiologist group: stop taking Ozempic before surgery

Doctors on social media are being harassed and cyberbullied

Guidelines to prevent youth baseball injuries need more muscle

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Activists slam private health insurers over coverage restrictions

AMAs digital advisors table RPM coding reform proposal, again

Medicare proposal to cover medical devices draws a mixed reaction

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

leisure time

Merck to acquire Harpoon Therapeutics for $680 million

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Gene therapy denied for Afghan refugee whose father aided U.S.

JPM pitch from hospitals? Revenue streams outside of patient care

Congress might make insulin pumps more accessible to the blind

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

explore

focus

focus